4basebio (LON:4BB) Trading Up 2% - Should You Buy?

Key Points

• 4basebio PLC's stock price rose by 2% to GBX 989 ($13.13) with a significant decline in trading volume, dropping to approximately 448 shares.
• The company reported a quarterly earnings loss of GBX (0.94) (($0.01)) per share and is projected to post an annual loss of -3.43 earnings per share for the fiscal year.
• With a market capitalization of £126.69 million, 4basebio specializes in developing therapeutic synthetic DNA for gene therapies and gene-based vaccines.

4basebio PLC (LON:4BB - Get Free Report)'s stock price rose 2% during mid-day trading on Friday . The company traded as high as GBX 990 ($13.16) and last traded at GBX 989 ($13.15). Approximately 448 shares traded hands during mid-day trading, a decline of 58% from the average daily volume of 1,069 shares. The stock had previously closed at GBX 970 ($12.90).

4basebio Price Performance

The company has a debt-to-equity ratio of 201.47, a current ratio of 2.73 and a quick ratio of 3.52. The firm's 50 day simple moving average is GBX 1,009.10 and its 200 day simple moving average is GBX 1,094.45. The stock has a market capitalization of £128.10 million, a PE ratio of -1,282.05 and a beta of 1.09.

4basebio (LON:4BB - Get Free Report) last released its earnings results on Tuesday, May 27th. The company reported GBX (0.94) (($0.01)) earnings per share for the quarter. As a group, equities analysts forecast that 4basebio PLC will post -3.43 EPS for the current fiscal year.

About 4basebio

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients. Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients.